Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FMDV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $68,330
Award facts
- Contract value 100% obligated
- $68,329.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a delivery order valued at $68,329.52 for 300 mg vials of Entyvio on November 4, 2025. This firm fixed-price delivery order, issued by the Defense Logistics Agency without a set-aside designation, represents a direct purchase of specialty pharmaceutical inventory to support Department of Defense medical supply requirements. The award reflects DMS Pharmaceutical Group's established capability as a critical supplier within the federal pharmaceutical supply chain, demonstrating the company's competitive positioning in unrestricted federal procurement.
This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, positioning the company as a regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy. The contract authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally, with DMS Pharmaceutical Group serving as one of multiple qualified suppliers under this strategic framework.
Quick answers
Who was awarded contract SPE2DR26FMDV3?
SPE2DR26FMDV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FMDV3 worth?
The government has obligated $68,330 on SPE2DR26FMDV3.
Is contract SPE2DR26FMDV3 an order under another contract?
Yes. SPE2DR26FMDV3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDV3 competed?
The extent of competition for SPE2DR26FMDV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award